ArticleOncoTargets and therapy2026
A Novel Strategy for Treating Elderly Patients with Advanced Non-Small Cell Lung Cancer: Exploring the Efficacy and Safety of Anlotinib Combined with PD-1/PD-L1 Inhibitors.
Article in OncoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to explore whether the combination of anlotinib and immunotherapy is an effective and safe alternative to chemotherapy for clinical treatment. Provide a new treatment plan for elderly patients who are unwilling to undergo chemotherapy, intolerant to chemotherapy, or have poor ECOG PS scores. Methods: This is a single-center retrospective investigation that collected clinical data of 58 elderly aNSCLC patients treated with anlotinib monotherapy or anlotinib plus PD-1/PD-L1 inhibitor combination therapy at Nanjing Chest Hospital during the period from January 1, 2020 to December 31, 2023, with the study being subject to a limited sample size. Results: Fifty-eight elderly patients were evaluated after two cycles of anlotinib monotherapy and combined therapy. In the monotherapy group of 28 patients, the ORR and DCR were 25.0% (7/28) and 78.6% (22/28), respectively. Besides, the mPFS and the mOS reached up to 5.4 months (95% CI, 4.4-6.4 months) and 11.2 months (95% CI, 7.2-15.2 months), respectively. In the group with combination therapy of 30cases, the ORR for this group was calculated at 30.0% (9/30), the DCR was higher, at 86.7% (26/30), the mPFS and the mOS were determined to be 8.5 months (95% CI, 7.3-9.7 months) and 17.8 months (95% CI, 13.2-22.4 months), respectively. In multivariate COX analysis, brain metastasis and treatment methods were found to be independent risk factors for PFS alongside OS. Both groups had a comparable overall incidence of adverse events (AEs), at 70.0% and 64.3% respectively, with no statistically significant difference noted in the rate of grade 3 and above adverse events (23.3% versus 17.9%). Conclusion: Anlotinib combined with immunotherapy demonstrated superior efficacy and better tolerability than anlotinib alone. The combination of anlotinib and immunotherapy may provide a "chemo-free" treatment mode for elderly patients with non-small cell lung cancer who refuse or cannot tolerate chemotherapy and have poor ECOG PS scores.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.